Press Releases

Press Releases

Date Title
10/07/21 New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model
Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccines Study suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals SOUTH SAN FRANCISCO,
10/06/21 Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
Start of US Phase II of S-Only Vaccine Candidate Expected Later This Month Ex-US Clinical Trials to Begin Later This Year with India Study SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II
09/27/21 Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer
Dr. Cummings Brings Nearly Three Decades of Experience to New Role SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F. Cummings , M.D., as the Company's Chief Medical Officer (CMO). Dr.
09/22/21 Vaxart To Present at Upcoming Vaccine Conferences
One of Company's Senior Scientists To Present at ID Week 2021 and 15th Vaccine Congress SOUTH SAN FRANCISCO, Calif. , Sept. 22, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and
09/21/21 Vaxart Announces Creation of Manufacturing and Quality Advisory Board
Leaders in the Pharmaceutical Industry To Advise Vaxart As It Advances Its Manufacturing Capabilities SOUTH SAN FRANCISCO, Calif. , Sept. 21, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.       "We are very excited
09/20/21 Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30
SOUTH SAN FRANCISCO , Sept. 20, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m.
09/07/21 Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 7, 2021 /PRNewswire/ --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu , President and CEO, and Dr. Sean Tucker , SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23 rd Annual Global Investor Conference taking place Sept.
08/23/21 Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
Dr. Cherrington brings decades of research and development experience and executive leadership to Vaxart's Board SOUTH SAN FRANCISCO, Calif. , Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington , Ph.D., to the company's board of directors.
08/19/21 Vaxart Announces Creation of New Scientific and Clinical Advisory Board
Leaders in Health Care, Vaccines, and Academic Research to Advise Vaxart as it Progresses Its Ground-Breaking Technology SOUTH SAN FRANCISCO, Calif. , Aug. 19, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board . 
08/05/21 Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
Company makes advances with its disruptive oral vaccine portfolio Cash, cash equivalents, and marketable securities of $198.9 million as of June 30, 2021 SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2021 /PRNewswire/ --  Vaxart, Inc. (Nasdaq: VXRT) issued its business update today for the second quarter